Search Results - "Posvar, Edward L"

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers by Bockbrader, Howard N., Radulovic, Louis L., Posvar, Edward L., Strand, James C., Alvey, Christine W., Busch, Janice A., Randinitis, Edward J., Corrigan, Brian W., Haig, George M., Boyd, Rebecca A., Wesche, David L.

“…Pregabalin has shown clinical efficacy for treatment of neuropathic pain syndromes, partial seizures, and anxiety disorders. Five studies in healthy volunteers…”
Get full text

Pregabalin Drug Interaction Studies: Lack of Effect on the Pharmacokinetics of Carbamazepine, Phenytoin, Lamotrigine, and Valproate in Patients with Partial Epilepsy by Brodie, Martin J., Wilson, Elaine A., Wesche, David L., Alvey, Christine W., Randinitis, Edward J., Posvar, Edward L., Hounslow, Neil J., Bron, Nicola J., Gibson, G. L., Bockbrader, Howard N.

“…Purpose: Pregabalin (PGB) is an α2‐δ ligand with demonstrated efficacy in epilepsy, neuropathic pain, and anxiety disorders. PGB is highly efficacious as…”
Get full text

Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function by Randinitis, Edward J., Posvar, Edward L., Alvey, Christine W., Sedman, Allen J., Cook, Jack A., Bockbrader, Howard N.

“…The objectives of this study were to determine the single‐dose pharmacokinetics of pregabalin in subjects with various degrees of renal function, determine the…”
Get full text

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects by Cilla, Jr, D D, Whitfield, L R, Gibson, D M, Sedman, A J, Posvar, E L

“…This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an investigational inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A…”
Get more information

Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children by Haig, George M., Bockbrader, Howard N., Wesche, David L., Boellner, Samuel W., Ouellet, Daniele, Brown, Richard R., Randinitis, Edward J., Posvar, Edward L.

“…Gabapentin (Neurontin®) is a gamma‐aminobutyric acid analogue indicated in adults for adjunctive treatment of partial seizures with or without secondary…”
Get full text

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects by Posvar, E L, Radulovic, L L, Cilla, Jr, D D, Whitfield, L R, Sedman, A J

“…Tolerance and pharmacokinetics after single-dose administration of atorvastatin, an investigational inhibitor of HMG-CoA reductase, were examined in 22 healthy…”
Get more information

Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol by Boyd, Rebecca A, Zegarac, Elizabeth A, Posvar, Edward L, Flack, Mary R

“…The pharmacokinetics and androgenic activity of Estrostep ®, a new oral contraceptive providing low-dose estrogen in a graduated sequence with a constant dose…”
Get full text

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor by Radulovic, L L, Cilla, D D, Posvar, E L, Sedman, A J, Whitfield, L R

“…To determine whether atorvastatin, a new HMG-CoA reductase inhibitor, could be administered with food in Phase II and III clinical trials, a nonblind,…”
Get more information

Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis by Blum, R A, Olson, S C, Kohli, R K, Horvath, A M, Sedman, A J, Posvar, E L

“…The pharmacokinetics of quinapril and its active metabolite, quinaprilat, were evaluated in 12 patients with end-stage renal disease (ESRD) on chronic…”
Get more information

Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children by Haig, George M, Bockbrader, Howard N, Wesche, David L, Boellner, Samuel W, Ouellet, Daniele, Brown, Richard R, Randinitis, Edward J, Posvar, Edward L

“…Gabapentin [1-(aminomethyl) cyclohexaneacetic acid; Neurontin super(+)] is an antiepileptic drug that is struc-Gabapentin (Neurontin super(+)) is a…”
Get full text

Lack of interaction of gabapentin with carbamazepine or valproate by Radulovic, L L, Wilder, B J, Leppik, I E, Bockbrader, H N, Chang, T, Posvar, E L, Sedman, A J, Uthman, B M, Erdman, G R

“…Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n = 12) or valproate (VPA, n = 14) monotherapy. The effects of…”
Get more information

The temporal effect of food on tacrine bioavailability by Welty, D F, Siedlik, P H, Posvar, E L, Selen, A, Sedman, A J

“…A four-way cross-over study was performed to assess the temporal effect of food on the rate and extent of tacrine (Cognex, THA) absorption after drug…”
Get more information

Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure by Mitrovic, V, Mudra, H, Bonzel, T, Schmidt, W, Strand, J C, Bakovic-Alt, R, Posvar, E L

“…To assess the pharmacodynamic activity and safety of rising single and multiple doses of intravenous quinaprilat compared with placebo in patients with New…”
Get more information

New drugs: first time in man by Posvar, E L, Sedman, A J

Get more information

ACE inhibitors in the elderly by Posvar, E L, Sedman, A J

“…As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the…”
Get more information

The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function by Halstenson, C E, Opsahl, J A, Rachael, K, Olson, S C, Horvath, A M, Abraham, P A, Posvar, E L

“…Single- and multiple-dose pharmacokinetics of quinapril and its active metabolite, quinaprilat, were determined after oral administration of 20 mg quinapril…”
Get more information

Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure by Munger, M A, Chance, M, Nair, R, Prescott, A W, Nara, A R, Simonson, M S, Green, J A, Posvar, E L

“…Quinapril, a nonsulfhydryl ACE inhibitor, was evaluated in ten New York Heart Association (NYHA) functional class (FC) II-III CHF patients to determine its…”
Get more information

Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia by Sramek, J J, Eldon, M A, Posvar, E, Feng, M R, Jhee, S S, Hourani, J, Sedman, A J, Cutler, N R

“…CI-1007 is a novel dopamine autoreceptor agonist and partial dopamine D2/D3 agonist that is currently under development for the treatment of schizophrenia…”
Get more information